FOLD

Amicus Therapeutics, Inc. (FOLD) | Rumor.io

Amicus Therapeutics

FOLD

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about FOLD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% -0.01	0% +0	0% 0

Jan 5

Amicus Therapeutics, Inc. (FOLD) is not mentioned as a company with a significant market cap, in contrast to another biotech company Mainz Biomed N.V.
The author believes that NextNRG Inc. (NXXT) has early innings upside potential, with a potential price target of $2.40.
Algorhythm Holdings, Inc. (RIME) is seen as a company with potential, showing 10–25% efficiency gains and an ignition point of $5.5, with no mention of FOLD.

Generated by AI

Sentiment

Of the messages about FOLD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.82% +17
Bearish	—	—	—	4.18% -17

Bullish· Dec 19

The acquisition of $FOLD by $BMRN is expected to be accretive to EPS in the first year post-close.
$FOLD's rare disease therapies, including Fabry and Pompe, are experiencing rapid growth, with sales reaching $77.5 million in the first nine months.
The deal is seen as a transformative acquisition for $BMRN, expanding its position as a leader in rare diseases and accelerating revenue growth.

Bearish· Feb 12

Analysts have downgraded $FOLD, with targets ranging from $15 to $19, citing concerns over its cap structure, cash burn, and limited IP coverage for Galafold.
Recent test results for Amicus Therapeutics' Pompe disease drug have been disappointing, leading to a tanking of the stock and further downgrades from analysts.
SVB Leerink has downgraded $FOLD, reducing its price target from $30 to $15, citing concerns over the approvability of Amicus Therapeutics' PROPEL drug.

Generated by AI

Topics

Of the messages about FOLD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	30.86%
Announcements	—	—	100%	61.57%
Controversies	—	—	0%	0.84%
Earnings	—	—	0%	0.84%
Macro	—	—	0%	2.83%
Technical Analysis	—	—	0%	3.06%

Announcements· Dec 19

BioMarin is acquiring Amicus Therapeutics for $4.8 billion, with a deal price of $14.50 per share, representing a 33% premium over the previous closing price.
The acquisition adds two marketed, high-growth products to BioMarin's portfolio, including Galafold for Fabry disease and Pombiliti and Opfolda for Pompe disease, with combined revenue of $599 million over the past four quarters.
The deal is expected to close in the second quarter of 2026, subject to regulatory approvals and shareholder vote, and is seen as a strategic move to enhance BioMarin's position as a leader in rare diseases.

Controversies· May 24

There is no mention of Amicus Therapeutics, Inc. or its asset FOLD in the provided social media post, which primarily discusses Ripple v. SEC.
The post mentions Amicus Therapeutics, Inc. only in a list of companies, including Ripple, that Attorney John Deaton is requesting leave to file an amicus brief for.
The post does not mention FOLD at all, and the company Amicus Therapeutics, Inc. is not the main subject being discussed.

Technical Analysis· Aug 20

$FOLD is forming a bull flag continuation pattern with increasing volume.
The stock has broken through key support levels, including 5.30 and 5.11, and is approaching resistance at 5.70.
Technical indicators, such as ADX and RSI, suggest strong buying momentum and potential for further price increases.

Generated by AI

Community

Of the messages about FOLD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	20.29%
Newcomers	—	—	100%	79.71%

Regulars· Dec 19

BioMarin is acquiring Amicus Therapeutics for $4.8B, expanding its rare disease product portfolio with Galafold, Pombiliti, and Opfolda, and expected to close in Q2 2026.
The acquisition price is $14.50 per share, representing a 33%+ premium to Amicus Therapeutics' last close, and the deal is expected to enhance BioMarin's leadership in rare diseases and accelerate revenue growth.
The acquisition is seen as a strategic move to strengthen BioMarin's financial outlook and expand its position as a leader in rare diseases, with Galafold and Pombiliti adding $599M in recent revenues to its portfolio.

Newcomers· Jan 5

Main concerns among newcomers include the asset's price ($15M cap), sensitivity and specificity in pancreas trials, and the potential for a 95% drop.
The accumulation thesis is being validated by volume confirmation, and the first stop is set at 4.5.
Newcomers are watching VWAP holds and higher lows, and see tech alignment with the story, with a near-term target of 4.5.

Generated by AI

News

BioMarin: Commercial Infrastructure Is The Hidden Growth Asset

2mo agoSeeking Alpha

Also Discussed

Investors talking about FOLD also mention

#	Name	Attention
1	BioMarin Pharmaceutical IncBMRN	0%+0
2	Halozyme Therapeutics Inc.HALO	0%0
3	Exelixis Inc.EXEL	0%-0.03
4	Acadia Pharmaceuticals Inc.ACAD	0%+0
5	MACK - Merrimack Pharmaceuticals, Inc.	——
6	Celldex Therapeutics IncCLDX	0%+0
7	HZNP - Horizon Therapeutics Public Limited Company	——
8	Sarepta Therapeutics, Inc.SRPT	0%-0.01
9	Neurocrine Biosciences, Inc.NBIX	0%new
10	Puma Biotechnology, Inc.PBYI	0%0